๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Genetic surrogate endpoint biomarkers in early breast neoplasia

โœ Scribed by Leslie Brand

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
62 KB
Volume
53
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

โœฆ Synopsis

Carolina) discussed the relationship of oncogenes and breast cancer. Specifically, he described much of the recent work with HER-2/neu, PRADI, and p53. Some of these genetic lesions appear early in the breast cancer process and are stable as the tumors become invasive and metastasize. Dr. Liu also presented a short sum-

๐Ÿ“œ SIMILAR VOLUMES

Genetic surrogate endpoint biomarkers in
Genetic surrogate endpoint biomarkers in early breast neoplasia
โœ D. Craig Allred ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 105 KB

## Genetic Surrogate Endpoint Biomarkers in Early Breast Neoplasia "Biomarkers in Early Breast Neoplasia," presented by D. Craig Allred. The biological mechanisms of breast cancer evolution are poorly understood. Furthermore, this problem has been difficult to study because potential precursor les

Intraepithelial neoplasia, surrogate end
Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
โœ Dr. Charles W. Boone; Gary J. Kelloff ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 930 KB

Neoplasia is a progression of molecular, cellular, and tissue changes starting with a critical cell mutation and advancing by clonal evolution, involving further multiple mutations and expanding mutated clones. This process is characterized by five general stages: latency, focal growth of normal-app

Biomarkers in early breast neoplasia
Biomarkers in early breast neoplasia
โœ D. Craig Allred; Peter O'Connell; Suzanne A. W. Fuqua ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 578 KB

Early breast neoplasia may be defined in many ways. Any non-invasive or invasive but nonmetastatic breast cancer qualifies as early neoplasia in the sense that they are non-lethal. Before we can prevent lethal breast cancer, we must gain a better understanding of the biological abnormalities underly

A phase II chemoprevention trial design
A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer
โœ Kapil Dhingra ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 434 KB

Surrogate biomarkers for risk assessment and efficacy of potential chemopreventive agents are needed to improve the efficiency and reduce the cost of conducting chemoprevention trials. In addition to criteria of sensitivity, specificity, quantifiability, and reproducibility applicable to most potent